CS
REGN icon

Cannell & Spears’s Regeneron Pharmaceuticals REGN Stock Holding History

Cannell & Spears’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Sell
36,099
-32,815
-48% -$22.3M 0.4% 66
2026
Q1 		$53.2M Sell
68,914
-20,481
-23% -$15.7M 1.04% 27
2025
Q4 		$69M Buy
89,395
+59,316
+197% +$40.3M 1.29% 22
2025
Q3 		$16.9M Buy
30,079
+3,618
+14% +$2.05M 0.32% 86
2025
Q2 		$13.9M Sell
26,461
-38,065
-59% -$21.2M 0.28% 86
2025
Q1 		$40.9M Buy
64,526
+48,471
+302% +$33.3M 0.88% 34
2024
Q4 		$11.4M Buy
16,055
+5,415
+51% +$4.54M 0.23% 91
2024
Q3 		$11.2M Buy
10,640
+78
+0.7% +$86.8K 0.22% 96
2024
Q2 		$11.1M Sell
10,562
-277
-3% -$269K 0.23% 90
2024
Q1 		$10.4M Buy
+10,839
New +$10.3M 0.22% 98

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cannell & Spears's REGN Position: Q2 2026 in Review

Cannell & Spears reduced its Regeneron Pharmaceuticals (REGN) stake by 48% in Q2 2026, selling an estimated $22.3M and leaving 36,099 shares worth $22.5M. The position accounts for 0.4% of the portfolio, ranked #66.

Cannell & Spears first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $69M in Q4 2025. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cannell & Spears held 36,099 shares of Regeneron Pharmaceuticals worth $22.5M as of Q2 2026.
  • Cannell & Spears sold 32,815 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $22.3M.
  • Regeneron Pharmaceuticals made up 0.4% of Cannell & Spears's portfolio in Q2 2026, its #66 holding.
  • Cannell & Spears first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Cannell & Spears's Regeneron Pharmaceuticals position peaked at $69M in Q4 2025.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cannell & Spears's 13F filing for Q2 2026, filed 11 Aug 2026.